May 6, 2015
Primary endpoint of preventing delayed CINV met with high significanceCambridge, UK - 6th May 2015: Acacia Pharma Ltd (Acacia Pharma" or "the Company"), a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention...


DNA analysis of 442 Viking skeletons rewrites the story of Viking culture
16. September 2020
Hope that a brain injection could cure type 2 diabetes
7. September 2020
Maude has become the stereotypical migraine patient – but it’s not quite the true picture
31. July 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge